Company Filing History:
Years Active: 2011-2015
Title: Sandeep Basra: Innovator in Integrin Inhibition
Introduction
Sandeep Basra is a notable inventor based in Munich, Germany. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of integrin inhibitors. With a total of 2 patents, his work focuses on novel compounds that have therapeutic applications.
Latest Patents
Sandeep Basra's latest patents include innovative compounds that inhibit the integrin α2β1/GPIa-IIa receptor. The first patent describes inhibitors based on a prolyl diaminopropionic acid scaffold. These compounds are disclosed along with pharmaceutical compositions and methods for their therapeutic use. They are particularly useful as inhibitors of integrin α2β1/GPIa-IIa-mediated activity. The second patent also focuses on inhibitors of integrin α2β1, specifically those with a modified urea moiety. Similar to the first, this patent outlines the compounds, their pharmaceutical compositions, and their therapeutic applications.
Career Highlights
Sandeep Basra is affiliated with the University of Pennsylvania, where he continues to advance research in integrin inhibition. His work has garnered attention for its potential impact on therapeutic strategies in various medical conditions.
Collaborations
He collaborates with esteemed colleagues, including Meredith W. Miller and Joel S. Bennett, who contribute to his research endeavors.
Conclusion
Sandeep Basra's innovative work in the field of integrin inhibitors showcases his commitment to advancing pharmaceutical science. His patents reflect a dedication to developing effective therapeutic solutions.